Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis

D S Bakker; L F M Ariens; C van Luijk; J van der Schaft; J L Thijs; M L A Schuttelaar; F van Wijk; E F Knol; D M W Balak; M R van Dijk; M S de Bruin-Weller

doi:10.1111/bjd.17538

Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis

D S Bakker, L F M Ariens, C van Luijk, J van der Schaft, J L Thijs, M L A Schuttelaar, F van Wijk, E F Knol, D M W Balak, M R van Dijk, M S de Bruin-Weller

Research output: Contribution to journal › Article › Academic › peer-review

4 Downloads (Pure)

Abstract

Higher rates of conjunctivitis have been reported in atopic dermatitis (AD) patients treated with dupilumab, an anti-interleukin (IL)-4Rα antibody inhibiting IL-4 and IL-13, compared to patients treated with placebo.1 However, the exact pathomechanism has not been clarified. Given the necessity of optimal treatment and risk management, the aim of this study was to describe the histopathological characteristics of conjunctivitis during dupilumab treatment in AD patients.

Original language	English
Pages (from-to)	1248-1249
Number of pages	2
Journal	British Journal of Dermatology
Volume	180
Issue number	5
Early online date	30 Dec 2018
DOIs	https://doi.org/10.1111/bjd.17538 https://doi.org/10.1111/bjd.17538
Publication status	Published - 1 May 2019

Access to Document

bakkerFinal published version, 253 KB

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85061057111&doi=10.1111%2fbjd.17538&partnerID=40&md5=af6435e5e8edc84f73de031b7b669368

Cite this

Bakker, D. S., Ariens, L. F. M., van Luijk, C., van der Schaft, J., Thijs, J. L., Schuttelaar, M. L. A., van Wijk, F., Knol, E. F., Balak, D. M. W., van Dijk, M. R., & de Bruin-Weller, M. S. (2019). Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. British Journal of Dermatology, 180(5), 1248-1249. https://doi.org/10.1111/bjd.17538, https://doi.org/10.1111/bjd.17538

@article{7aebece8a18f432eb98e97a587b27984,

title = "Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis",

abstract = "Higher rates of conjunctivitis have been reported in atopic dermatitis (AD) patients treated with dupilumab, an anti-interleukin (IL)-4Rα antibody inhibiting IL-4 and IL-13, compared to patients treated with placebo.1 However, the exact pathomechanism has not been clarified. Given the necessity of optimal treatment and risk management, the aim of this study was to describe the histopathological characteristics of conjunctivitis during dupilumab treatment in AD patients.",

author = "Bakker, {D S} and Ariens, {L F M} and {van Luijk}, C and {van der Schaft}, J and Thijs, {J L} and Schuttelaar, {M L A} and {van Wijk}, F and Knol, {E F} and Balak, {D M W} and {van Dijk}, {M R} and {de Bruin-Weller}, {M S}",

year = "2019",

month = may,

day = "1",

doi = "10.1111/bjd.17538",

language = "English",

volume = "180",

pages = "1248--1249",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Wiley-Blackwell",

number = "5",

}

Bakker, DS, Ariens, LFM, van Luijk, C, van der Schaft, J, Thijs, JL, Schuttelaar, MLA, van Wijk, F , Knol, EF, Balak, DMW, van Dijk, MR & de Bruin-Weller, MS 2019, 'Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis', British Journal of Dermatology, vol. 180, no. 5, pp. 1248-1249. https://doi.org/10.1111/bjd.17538, https://doi.org/10.1111/bjd.17538

TY - JOUR

T1 - Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis

AU - Bakker, D S

AU - Ariens, L F M

AU - van Luijk, C

AU - van der Schaft, J

AU - Thijs, J L

AU - Schuttelaar, M L A

AU - van Wijk, F

AU - Knol, E F

AU - Balak, D M W

AU - van Dijk, M R

AU - de Bruin-Weller, M S

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Higher rates of conjunctivitis have been reported in atopic dermatitis (AD) patients treated with dupilumab, an anti-interleukin (IL)-4Rα antibody inhibiting IL-4 and IL-13, compared to patients treated with placebo.1 However, the exact pathomechanism has not been clarified. Given the necessity of optimal treatment and risk management, the aim of this study was to describe the histopathological characteristics of conjunctivitis during dupilumab treatment in AD patients.

AB - Higher rates of conjunctivitis have been reported in atopic dermatitis (AD) patients treated with dupilumab, an anti-interleukin (IL)-4Rα antibody inhibiting IL-4 and IL-13, compared to patients treated with placebo.1 However, the exact pathomechanism has not been clarified. Given the necessity of optimal treatment and risk management, the aim of this study was to describe the histopathological characteristics of conjunctivitis during dupilumab treatment in AD patients.

UR - http://www.scopus.com/inward/record.url?scp=85061057111&partnerID=8YFLogxK

U2 - 10.1111/bjd.17538

DO - 10.1111/bjd.17538

M3 - Article

C2 - 30597515

SN - 0007-0963

VL - 180

SP - 1248

EP - 1249

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 5

ER -

Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis

Abstract

Access to Document

Other files and links

Fingerprint

Cite this